Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1740279 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $1.07Day −3.60%Mkt cap $11M1Y −51.4%Off 52W high −60.8%Vol (1Y) 81.8%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,248 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest0.2% of sh out |
| Days to cover1.0d |
| 13F net flow (QoQ)+4.84% |
| Top-10 13F concentration98.3% |
| Next report (est.)2026-08-06 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-$19.0M |
| ROE−92.5% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−54.3% |
| 1Y−51.4% |
| 3Y−97.0% |
| Since incept. (ann.)−67.8% |
Total return through 2026-07-29 · series begins 2021-08-02. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)81.8% |
| Ann. volatility (3Y)112.9% |
| Sharpe (1Y)−0.58 |
| Sharpe (3Y)−0.55 |
| Max drawdown (1Y)−58.7% |
| Max drawdown (3Y)−98.5% |
| Beta (3Y vs SPY)1.04 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Alyeska Investment Group, L.P. | 944,319 | $1M | 9.59% | −1.4% |
| FRANKLIN RESOURCES INC | 914,531 | $1M | 9.29% | +0.0% |
| 683 Capital Management, LLC | 724,637 | $1M | 7.36% | +0.0% |
| Stonepine Capital Management, LLC | 663,412 | $981,850 | 6.74% | +302.3% |
| BIOS Capital Management, LP | 167,805 | $248,351 | 1.70% | −33.8% |
| VANGUARD CAPITAL MANAGEMENT LLC | 88,865 | $131,965 | 0.90% | new |
| GEODE CAPITAL MANAGEMENT, LLC | 86,239 | $127,635 | 0.88% | +311.3% |
| VANGUARD FIDUCIARY TRUST CO | 43,570 | $64,701 | 0.44% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | −$0.26 | — | — | — |
| 2025-09-30 | 2025-11-06 | −$0.85 | — | — | — |
| 2025-06-30 | 2025-08-07 | −$1.24 | — | — | — |
| 2025-03-31 | 2025-05-07 | — | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-06 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
